Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Other Non-Current Liabilities (2017 - 2023)

Historic Other Non-Current Liabilities for Denali Therapeutics (DNLI) over the last 7 years, with Q3 2023 value amounting to $379000.0.

  • Denali Therapeutics' Other Non-Current Liabilities changed 0.0% to $379000.0 in Q3 2023 from the same period last year, while for Sep 2023 it was $379000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $379000.0 for FY2022, which is 0.0% changed from last year.
  • Denali Therapeutics' Other Non-Current Liabilities amounted to $379000.0 in Q3 2023, which was down 0.0% from $379000.0 recorded in Q2 2023.
  • Denali Therapeutics' Other Non-Current Liabilities' 5-year high stood at $701000.0 during Q4 2020, with a 5-year trough of $379000.0 in Q4 2019.
  • Over the past 5 years, Denali Therapeutics' median Other Non-Current Liabilities value was $379000.0 (recorded in 2019), while the average stood at $451894.7.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first soared by 21129.03% in 2019, then crashed by 4593.44% in 2021.
  • Over the past 5 years, Denali Therapeutics' Other Non-Current Liabilities (Quarter) stood at $379000.0 in 2019, then soared by 84.96% to $701000.0 in 2020, then crashed by 45.93% to $379000.0 in 2021, then changed by 0.0% to $379000.0 in 2022, then changed by 0.0% to $379000.0 in 2023.
  • Its Other Non-Current Liabilities stands at $379000.0 for Q3 2023, versus $379000.0 for Q2 2023 and $379000.0 for Q1 2023.